Compare Incyte Corporation (INCY) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Sibanye Stillwater Ltd — how do they compare? Incyte Corporation trades at $117.76 (market cap $23.11B), while Sibanye Stillwater Ltd trades at $8.33 (market cap $5.66B). The key difference: Incyte Corporation is far larger — about 4.1× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays a 3.89% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SBSW | |
|---|---|---|
Market Cap | $23.11B | $5.66B |
Sector | Health | Basic Materials |
52-Week High | $118.52 | $21.12 |
52-Week Low | $67.38 | $7.27 |
Enterprise Value | $19.13B | $7.28B |
Dividend Yield | — | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Sibanye Stillwater (SBSW) trades at $8.02, up 0.25% on the day, with technical indicators showing a bearish trend. The company reported a net loss of $7.30 billion in 2024, though revenue remained stable at $112.13 billion. Recent news highlights management's focus on debt reduction and operational improvements, with Seeking Alpha noting a 5x YoY EBITDA surge driven by strong PGM and gold prices as of July 3, 2026.
The stock presents a high-risk opportunity with a consensus price target of $14.25, implying significant upside, but faces headwinds from negative profitability metrics and volatile commodity prices. Investors should weigh the potential turnaround against ongoing operational challenges and macroeconomic risks in the mining sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
